Product Description
An innovative oral C5 inhibitor engineered for optimal potency, gastrointestinal stability and extended half-life. These properties of our proprietary compound will translate into enhanced efficacy and a compelling oral solution for patients seeking more accessible and convenient therapies. (Sourced from: https://nimbletherapeutics.com/our-pipeline/)
Mechanisms of Action: C5 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nimble Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Myasthenia Gravis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|